Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Abbott Laboratories pages available for free this week:
- Balance Sheet: Assets
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Dividend Discount Model (DDM)
- Net Profit Margin since 2005
- Current Ratio since 2005
- Total Asset Turnover since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Abbott Laboratories for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The solvency position, as indicated by the presented ratios, demonstrates a generally strengthening financial structure over the analyzed period spanning from March 2022 to December 2025. A consistent pattern of decreasing leverage is observed, alongside improving coverage of interest obligations. These trends suggest a reduced reliance on debt financing and an enhanced ability to meet financial commitments.
- Debt to Equity
- The debt to equity ratio exhibits a steady decline from 0.48 in March 2022 to 0.25 by December 2025. This indicates a decreasing proportion of financing derived from debt relative to equity, suggesting a lower risk profile and increased financial flexibility. The rate of decline accelerates in the latter half of the period, particularly after September 2023.
- Debt to Capital
- Mirroring the trend in debt to equity, the debt to capital ratio also shows a consistent decrease, moving from 0.33 in March 2022 to 0.20 in December 2025. This reinforces the observation of a diminishing reliance on debt within the overall capital structure. The reduction is relatively consistent quarter-over-quarter.
- Debt to Assets
- The debt to assets ratio follows a similar downward trajectory, decreasing from 0.23 in March 2022 to 0.15 by December 2025. This signifies a smaller proportion of assets financed by debt, further supporting the conclusion of a strengthening solvency position. The most significant decrease occurs between December 2023 and December 2025.
- Financial Leverage
- Financial leverage, as measured by the ratio, declines from 2.09 in March 2022 to 1.66 in December 2025. This indicates a reduced magnification of both profits and losses due to debt financing. The decrease is not strictly linear, with some quarterly fluctuations, but the overall trend is clearly downward.
- Interest Coverage
- The interest coverage ratio demonstrates a generally increasing trend, starting at 18.10 in March 2022 and reaching 18.17 in December 2025. While there are intermediate fluctuations, the overall improvement suggests a greater ability to cover interest expenses from earnings before interest and taxes. The ratio experienced a dip between March 2022 and December 2022, but has since recovered and surpassed its initial level.
In summary, the observed trends across all ratios consistently point towards an improving solvency profile. The company appears to be strategically reducing its debt burden and enhancing its capacity to service its debt obligations, indicating a strengthening financial foundation.
Debt Ratios
Coverage Ratios
Debt to Equity
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Short-term borrowings | |||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Total Abbott shareholders’ investment | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to equity = Total debt ÷ Total Abbott shareholders’ investment
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio for the analyzed period demonstrates a consistent downward trend, indicating a strengthening of the company’s financial position with respect to its leverage. Initially, the ratio fluctuated around 0.46 to 0.48 before exhibiting a more pronounced decline in later periods.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The debt to equity ratio remained relatively stable, ranging between 0.45 and 0.48. Total debt decreased modestly from $17,090 million to $16,773 million, while total shareholders’ investment experienced a slight increase from $35,399 million to $36,686 million. This stability suggests a balanced approach to financing during this timeframe.
- Transitional Phase (Mar 31, 2023 – Dec 31, 2023)
- A gradual decrease in the debt to equity ratio is observed, moving from 0.46 to 0.38. This decline is attributable to a more significant reduction in total debt, falling from $16,900 million to $14,679 million, coupled with a continued, albeit slower, increase in total shareholders’ investment, rising from $37,010 million to $38,603 million. This suggests a deliberate effort to reduce reliance on debt financing.
- Accelerated Decline (Mar 31, 2024 – Dec 31, 2025)
- The rate of decline in the debt to equity ratio accelerates, decreasing from 0.38 to 0.25. Total debt continues to decrease substantially, reaching $12,929 million by December 31, 2025, from $14,586 million. Simultaneously, total shareholders’ investment experiences a more substantial increase, growing from $38,810 million to $52,130 million. This indicates a significant shift towards equity financing and a considerable improvement in the company’s solvency.
Overall, the observed trend suggests a proactive strategy to improve the company’s capital structure by reducing debt and increasing equity. The decreasing ratio implies a lower risk profile and greater financial flexibility.
Debt to Capital
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Short-term borrowings | |||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Total Abbott shareholders’ investment | |||||||||||||||||||||
| Total capital | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The debt to capital ratio for the analyzed period demonstrates a consistent, albeit gradual, decline. Initially, the ratio fluctuated around 0.32-0.33 before exhibiting a more pronounced downward trend in the latter half of the period. This suggests a decreasing reliance on debt financing relative to the company’s total capital structure.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The debt to capital ratio began at 0.33 and decreased to 0.31 over this period. Total debt decreased from US$17,090 million to US$16,773 million, while total capital experienced a slight increase from US$52,489 million to US$53,459 million. This initial decrease indicates a modest improvement in the company’s solvency position.
- Stabilization Phase (Mar 31, 2023 – Dec 31, 2023)
- From March 31, 2023, to December 31, 2023, the ratio remained relatively stable, hovering around 0.31 and then decreasing to 0.28. Total debt decreased slightly from US$16,900 million to US$14,679 million, while total capital remained relatively consistent, fluctuating between US$53,910 million and US$53,282 million. This suggests a period of controlled debt management.
- Accelerated Decline (Mar 31, 2024 – Dec 31, 2025)
- A more significant decline in the debt to capital ratio is observed from March 31, 2024, onwards. The ratio decreased from 0.27 to 0.20 by December 31, 2025. This corresponds with a substantial reduction in total debt, falling from US$14,586 million to US$12,929 million, coupled with a notable increase in total capital, rising from US$53,396 million to US$65,059 million. This indicates a considerable strengthening of the company’s financial leverage and a shift towards equity financing or internally generated funds.
Overall, the trend suggests a deliberate strategy to reduce debt and/or increase capital, resulting in a more conservative capital structure. The accelerated decline in the latter portion of the analyzed period is particularly noteworthy, indicating a potentially significant improvement in the company’s long-term financial stability.
Debt to Assets
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Short-term borrowings | |||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The debt-to-assets ratio remained relatively stable for the initial portion of the observed period, then demonstrated a consistent downward trend. Throughout the first three quarters of 2022 and the first two quarters of 2023, the ratio consistently registered at 0.23. A decline began in the third quarter of 2023, continuing through the end of the period examined.
- Overall Trend
- The debt-to-assets ratio exhibits a clear decreasing trend over the analyzed timeframe. Starting at 0.23, it progressively decreased to 0.15 by the final period.
- Initial Stability (Mar 31, 2022 – Jun 30, 2023)
- For approximately eighteen months, from March 31, 2022, to June 30, 2023, the ratio remained constant at 0.23. This indicates a consistent financial leverage position during this period.
- Decline Phase (Sep 30, 2023 – Dec 31, 2025)
- Beginning in September 2023, the ratio began a steady decline. It moved from 0.22 to 0.20 by the end of 2023, and continued to decrease to 0.17 by December 2024. The decline continued into 2025, reaching 0.15 by December 31, 2025.
- Magnitude of Change
- The ratio decreased by 0.08 over the entire period, representing a roughly 35% reduction in the proportion of assets financed by debt. This suggests a strengthening of the company’s financial position, with a reduced reliance on debt financing.
The observed trend suggests a deliberate strategy to reduce financial leverage or a change in asset composition. Further investigation into the underlying factors driving these changes in total debt and total assets would be necessary to provide a more comprehensive assessment.
Financial Leverage
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Total Abbott shareholders’ investment | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Financial leverage = Total assets ÷ Total Abbott shareholders’ investment
= ÷ =
2 Click competitor name to see calculations.
The financial leverage ratio for the analyzed period demonstrates a consistent, albeit gradual, downward trend. Initially, the ratio fluctuated around 2.0, then decreased steadily over the observed timeframe. This indicates a decreasing reliance on debt financing relative to equity.
- Overall Trend
- From March 31, 2022, to December 31, 2025, the financial leverage ratio declined from 2.09 to 1.66. The most significant decrease occurred between December 31, 2023, and December 31, 2024, moving from 1.90 to 1.71. A slight increase is observed in the final period, from 1.65 to 1.66.
- Short-Term Fluctuations (2022-2023)
- During the period from March 31, 2022, to June 30, 2023, the ratio exhibited minor fluctuations, remaining consistently above 1.9. This suggests a relatively stable capital structure during this timeframe. The decrease from 2.09 to 1.97 indicates a slight reduction in financial leverage.
- Long-Term Decline (2023-2025)
- The period from September 30, 2023, to December 31, 2025, shows a more pronounced and consistent decline in the ratio. This suggests a deliberate strategy to reduce debt or increase equity financing. The ratio decreased from 1.92 to 1.66 over this period, with the most substantial drop occurring in the first half of 2024.
- Asset and Equity Relationship
- Total assets experienced growth throughout the period, increasing from 74,007 million to 86,713 million. However, total shareholders’ investment grew at a faster rate, rising from 35,399 million to 52,130 million. This differential growth in equity relative to assets is the primary driver of the observed decrease in the financial leverage ratio.
The consistent decline in financial leverage suggests a strengthening financial position and reduced risk associated with debt obligations. The company appears to be increasingly funded by equity rather than debt.
Interest Coverage
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Net earnings | |||||||||||||||||||||
| Add: Income tax expense | |||||||||||||||||||||
| Add: Interest expense | |||||||||||||||||||||
| Earnings before interest and tax (EBIT) | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Interest coverage1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Interest Coverage, Competitors2 | |||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Interest coverage
= (EBITQ4 2025
+ EBITQ3 2025
+ EBITQ2 2025
+ EBITQ1 2025)
÷ (Interest expenseQ4 2025
+ Interest expenseQ3 2025
+ Interest expenseQ2 2025
+ Interest expenseQ1 2025)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The interest coverage ratio for the analyzed period demonstrates a generally declining trend from early 2022 through mid-2023, followed by a recovery and subsequent stabilization towards the end of the period. While fluctuations exist, the ratio consistently remains above 10, indicating a reasonable ability to meet interest obligations from earnings.
- Overall Trend
- The ratio began at 18.10 in March 2022, peaking at 20.07 in June 2022. A subsequent decline was observed through June 2023, reaching a low of 11.34. From September 2023 onwards, the ratio exhibited an upward trend, stabilizing around 16-18 by December 2025.
- EBIT Contribution
- Earnings before interest and tax (EBIT) generally decreased from $3,007 million in March 2022 to $1,474 million in December 2022. A gradual recovery in EBIT was then observed, reaching $2,478 million by December 2025. This recovery in EBIT is a key driver of the subsequent improvement in the interest coverage ratio.
- Interest Expense
- Interest expense remained relatively stable, fluctuating between $131 million and $166 million throughout the period. A slight decrease in interest expense from $166 million in September 2023 to $120 million in December 2025 contributed to the improved interest coverage ratio in the latter part of the analyzed timeframe.
- Period-Specific Observations
- The most significant decline in the interest coverage ratio occurred between March 2022 and June 2023, coinciding with a substantial decrease in EBIT and a moderate increase in interest expense. The subsequent improvement from September 2023 to December 2025 is attributable to both increasing EBIT and decreasing interest expense.
In conclusion, while the interest coverage ratio experienced a period of decline, it has demonstrated resilience and a recovery trend. The company maintains a comfortable margin of safety regarding its ability to cover interest payments, as indicated by the consistently high ratio values.